ADMA Biologics

ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons.

ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.

ADMA Biologics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Manufacturing sector. The company focuses on Biotechnology and has secured $190.0B in funding across 256 round(s). With a team of 51-100 employees, ADMA Biologics is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Debt - ADMA Biologics, raised $15.0M. Discover more about their projects, partnerships, and impact on our platform.